Biohaven Pharmaceutical (NYSE:BHVN) Stock Price Up 5%

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) rose 5% on Friday . The company traded as high as $48.37 and last traded at $48.33, approximately 567,449 shares were traded during trading. A decline of 20% from the average daily volume of 709,867 shares. The stock had previously closed at $46.01.

BHVN has been the subject of a number of recent research reports. Morgan Stanley set a $50.00 price objective on Biohaven Pharmaceutical and gave the company a “hold” rating in a research note on Friday, August 9th. William Blair reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 17th. Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. Oppenheimer set a $67.00 price objective on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Goldman Sachs Group set a $89.00 price objective on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $69.82.

The company has a 50 day moving average of $44.64 and a two-hundred day moving average of $48.09. The stock has a market cap of $2.45 billion, a PE ratio of -7.86 and a beta of 0.34.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.47). On average, analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -7.68 EPS for the current fiscal year.

In other Biohaven Pharmaceutical news, insider Elyse Stock sold 800 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total transaction of $36,008.00. Following the completion of the sale, the insider now directly owns 800 shares in the company, valued at approximately $36,008. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gregory Bailey acquired 5,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $37.65 per share, with a total value of $188,250.00. Following the completion of the purchase, the director now owns 2,587,601 shares in the company, valued at approximately $97,423,177.65. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 28,500 shares of company stock valued at $1,283,747. 23.90% of the stock is owned by company insiders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of large investors have recently bought and sold shares of the business. GW&K Investment Management LLC increased its stake in Biohaven Pharmaceutical by 41.5% during the 3rd quarter. GW&K Investment Management LLC now owns 146,376 shares of the company’s stock worth $6,107,000 after buying an additional 42,896 shares in the last quarter. Eagle Asset Management Inc. increased its stake in Biohaven Pharmaceutical by 0.3% during the 3rd quarter. Eagle Asset Management Inc. now owns 984,335 shares of the company’s stock worth $41,066,000 after buying an additional 2,939 shares in the last quarter. First Mercantile Trust Co. purchased a new stake in Biohaven Pharmaceutical during the 3rd quarter worth approximately $148,000. Trellus Management Company LLC increased its stake in Biohaven Pharmaceutical by 21.5% during the 3rd quarter. Trellus Management Company LLC now owns 7,900 shares of the company’s stock worth $330,000 after buying an additional 1,400 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Biohaven Pharmaceutical during the 3rd quarter worth approximately $801,000. Institutional investors own 90.74% of the company’s stock.

Biohaven Pharmaceutical Company Profile (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

See Also: Leveraged Buyout (LBO)

Leave a Reply

Your email address will not be published. Required fields are marked *

*